1. Academic Validation
  2. Prenylisoflavonoids from Erythrina senegalensis as novel HIV-1 protease inhibitors

Prenylisoflavonoids from Erythrina senegalensis as novel HIV-1 protease inhibitors

  • Planta Med. 2009 Feb;75(3):268-70. doi: 10.1055/s-0028-1088395.
Jisuk Lee 1 Won Keun Oh Jong Seog Ahn Yong Hae Kim J Tanyi Mbafor Jean Wandji Z Tanee Fomum
Affiliations

Affiliation

  • 1 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Kwanak-gu, Seoul, Korea. jslee103@snu.ac.kr
Abstract

Eight compounds were isolated from the CH (2)Cl (2) extracts of ERYTHRINA SENEGALENSIS to assess HIV-1 Protease (PR) activity inhibition. The prenylated isoflavone structures, identified by spectroscopic analysis, were 8-prenylluteone ( 1), auriculatin ( 2), erysenegalensein O ( 3), erysenegalensein D ( 4), erysenegalensein N ( 5), derrone ( 6), alpinumisoflavone ( 7), and 6,8-diprenylgenistein ( 8). The constituents showed dose-dependent inhibitory activities on HIV-1 PR with IC (50) values from 0.5 to 30.0 muM. Compounds 1 - 5 possessing two hydroxy groups in the 2' and 4' positions of the B ring, potently inhibited HIV-1 PR activity. In addition, 6,8-diprenylgenistein ( 8) with two prenyl groups in the 6 and 8 positions of the A ring and one hydroxy group in the 4' position of B-ring was the most potent HIV-1 PR inhibitor.

Figures
Products